ArticleBMC ophthalmology2021
Treatment of acute acquired concomitant esotropia.
Article in BMC ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Comparative efficacy of botulinum toxin and surgical treatment for acute acquired concomitant esotropia: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Pooled it
- Augmented medial rectus recession versus botulinum toxin therapy for acute acquired comitant esotropia: analysis of outcomes and recurrence predictors.The British journal of ophthalmology · 2026Trial
- Adult-Acquired Esotropia: Clinical Characteristics, Risk Factors and Outcomes of a Novel Surgical Approach.Journal of clinical medicine · 2026Article
- Botulinum toxin for acute acquired comitant esotropia: clinical outcomes and predictors.BMC ophthalmology · 2025Article
- Efficacy of botulinum toxin and surgery in managing acute acquired comitant esotropia.Eye and vision (London, England) · 2025Article
- Long-term efficacy of botulinum toxin for treatment of acquired non-accommodative comitant esotropia.Scientific reports · 2025Article
- Botulinum toxin A as a treatment modality for acute acquired comitant esotropia - An Indian perspective.Indian journal of ophthalmology · 2025Article
- Botulinum toxin-A in acute acquired comitant esotropia during COVID pandemic in children and young adolescents.Indian journal of ophthalmology · 2025Article
- 2021 trends in the treatment of patients with strabismus in Japan.Japanese journal of ophthalmology · 2025Article
- Acute-onset Concomitant Esotropia in Children: A Comparison of Clinical Features and Treatment Outcomes.Journal of ophthalmic & vision research · 2025Article
- Dose-Effect Relationship of Botulinum Toxin Type A in the Management of Strabismus: A Review.Cureus · 2024Review
- Advances in the diagnosis and treatment of acute acquired comitant esotropia.International ophthalmology · 2024Review
- Golden Indications and an Overview on the Use of Botulinum Toxin in Strabismus.Turkish journal of ophthalmology · 2023Article
- Deficits of Visual Cortex Function in Acute Acquired Concomitant Esotropia Patients.Investigative ophthalmology & visual science · 2023Article
- Botulinum Toxin Injection versus Extraocular Muscle Surgery for Acute Acquired Comitant Esotropia.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Prismatic treatment of acute acquired concomitant esotropia of 25 prism diopters or less.BMC ophthalmology · 2022Article
- Clinical features and treatment of near-work-related acquired esotropia.International journal of ophthalmology · 2022Article
- Acute acquired comitant esotropia: Current understanding of its etiological classification and treatment strategies.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe treatment efficacy of botulinum toxin bilateral medial rectus injections for acute acquired concomitant esotropia (AACE) in adult is not clear. We characterize the effects of botulinum toxin injection in the treatment of AACE, especially in patients over 14 years old, and compared it with surgical treatment.
methodsIn this prospective, nonrandomized, controlled clinical study, patients with AACE in our hospital from March 2017 to March 2020 elected to receive bilateral medial rectus injections of botulinum toxin or to undergo extraocular muscle surgery. Ocular position and stereopsis were evaluated before and after treatment.
resultsA total of 60 patients were treated: 40 patients in the botulinum toxin group, and 20 patients in the surgery group. The botulinum toxin group included 31 cases ≥ 14 years of age and 9 cases < 14 years of age. After 1-3 botulinum injections, the cumulative initial success rate was 95% (38/40), and the recurrence rate was 22.5% (9/40). Nine children < 14 years of age were treated successfully, without recurrence. In the surgery group, the initial success rate after surgery was 75% (17/20), and the recurrence rate was 20% (4/20). There was no significant difference between groups in the rate of success rate or the rate of recurrence (P > 0.05).
conclusionThe injection of botulinum toxin has a good effect on AACE in adults and children. The outcomes achieved with injected botulinum toxin are similar to those achieved with surgery.
trial registrationChiCTR, ChiCTR2000032544 . Registered May 2, 2020, Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.